Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Should You Sell?

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) gapped down before the market opened on Wednesday. The stock had previously closed at $32.87, but opened at $31.45. Nanobiotix shares last traded at $32.7350, with a volume of 4,674 shares.

Analyst Upgrades and Downgrades

NBTX has been the subject of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research note on Thursday, October 15th. Guggenheim assumed coverage on shares of Nanobiotix in a report on Tuesday, September 15th. They set a “buy” rating and a $64.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.67.

Nanobiotix Stock Down 0.8%

The company has a fifty day moving average price of $30.84 and a 200 day moving average price of $34.05.

Nanobiotix Company Profile

Nanobiotix is a French biotechnology company developing nanoparticle-based treatments for cancer. Founded in 2003, the company focuses on using nanomedicine to enhance the effects of established cancer therapies, particularly radiation therapy. Its lead product candidate, NBTXR3, is made from hafnium oxide nanoparticles and is designed to be injected directly into a tumor. When exposed to radiation, the particles are intended to increase damage to cancer cells while limiting the effect on surrounding healthy tissue.